nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexamethasone—PGR—ovarian cancer	0.172	0.454	CbGaD
Dexamethasone—CYP1B1—ovarian cancer	0.161	0.424	CbGaD
Dexamethasone—NOS2—Doxorubicin—ovarian cancer	0.053	0.133	CbGbCtD
Dexamethasone—ABCB1—ovarian cancer	0.0461	0.122	CbGaD
Dexamethasone—SLCO1A2—Chlorambucil—ovarian cancer	0.0433	0.108	CbGbCtD
Dexamethasone—ABCB11—Paclitaxel—ovarian cancer	0.0234	0.0587	CbGbCtD
Dexamethasone—CYP1B1—Paclitaxel—ovarian cancer	0.0234	0.0587	CbGbCtD
Dexamethasone—ABCG2—Topotecan—ovarian cancer	0.0225	0.0564	CbGbCtD
Dexamethasone—CYP19A1—Paclitaxel—ovarian cancer	0.019	0.0476	CbGbCtD
Dexamethasone—CYP1B1—Docetaxel—ovarian cancer	0.0169	0.0424	CbGbCtD
Dexamethasone—CYP1B1—Doxorubicin—ovarian cancer	0.0126	0.0316	CbGbCtD
Dexamethasone—ABCB11—Doxorubicin—ovarian cancer	0.0126	0.0316	CbGbCtD
Dexamethasone—ABCC2—Paclitaxel—ovarian cancer	0.0123	0.0309	CbGbCtD
Dexamethasone—ABCC2—Carboplatin—ovarian cancer	0.0116	0.029	CbGbCtD
Dexamethasone—ABCG2—Paclitaxel—ovarian cancer	0.0111	0.0279	CbGbCtD
Dexamethasone—ABCG2—Carboplatin—ovarian cancer	0.0105	0.0263	CbGbCtD
Dexamethasone—ABCC2—Docetaxel—ovarian cancer	0.00891	0.0223	CbGbCtD
Dexamethasone—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.00823	0.0206	CbGbCtD
Dexamethasone—CYP3A7—Paclitaxel—ovarian cancer	0.00823	0.0206	CbGbCtD
Dexamethasone—ABCB1—Topotecan—ovarian cancer	0.00812	0.0203	CbGbCtD
Dexamethasone—ABCG2—Docetaxel—ovarian cancer	0.00806	0.0202	CbGbCtD
Dexamethasone—ABCC2—Doxorubicin—ovarian cancer	0.00664	0.0166	CbGbCtD
Dexamethasone—CYP3A5—Paclitaxel—ovarian cancer	0.00617	0.0155	CbGbCtD
Dexamethasone—ABCG2—Doxorubicin—ovarian cancer	0.00601	0.015	CbGbCtD
Dexamethasone—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.00595	0.0149	CbGbCtD
Dexamethasone—CYP3A7—Docetaxel—ovarian cancer	0.00595	0.0149	CbGbCtD
Dexamethasone—CYP2C8—Paclitaxel—ovarian cancer	0.00594	0.0149	CbGbCtD
Dexamethasone—CYP19A1—follicular fluid—ovarian cancer	0.00581	0.0806	CbGeAlD
Dexamethasone—ABCB1—Vinorelbine—ovarian cancer	0.00572	0.0143	CbGbCtD
Dexamethasone—CYP2D6—Vinorelbine—ovarian cancer	0.00539	0.0135	CbGbCtD
Dexamethasone—CYP11A1—corpus luteum—ovarian cancer	0.00515	0.0715	CbGeAlD
Dexamethasone—CYP3A4—Topotecan—ovarian cancer	0.00486	0.0122	CbGbCtD
Dexamethasone—CYP3A5—Docetaxel—ovarian cancer	0.00446	0.0112	CbGbCtD
Dexamethasone—CYP17A1—ovarian follicle—ovarian cancer	0.00433	0.0601	CbGeAlD
Dexamethasone—CYP2B6—Doxorubicin—ovarian cancer	0.00422	0.0106	CbGbCtD
Dexamethasone—CYP2C9—Paclitaxel—ovarian cancer	0.00414	0.0104	CbGbCtD
Dexamethasone—CYP11A1—ovarian follicle—ovarian cancer	0.00403	0.0559	CbGeAlD
Dexamethasone—ABCB1—Paclitaxel—ovarian cancer	0.00402	0.0101	CbGbCtD
Dexamethasone—PGR—corpus luteum—ovarian cancer	0.00372	0.0516	CbGeAlD
Dexamethasone—CYP3A4—Vinorelbine—ovarian cancer	0.00343	0.00858	CbGbCtD
Dexamethasone—CYP19A1—corpus luteum—ovarian cancer	0.00335	0.0464	CbGeAlD
Dexamethasone—PGR—ovarian follicle—ovarian cancer	0.00291	0.0404	CbGeAlD
Dexamethasone—ABCB1—Docetaxel—ovarian cancer	0.00291	0.00727	CbGbCtD
Dexamethasone—CYP19A1—ovarian follicle—ovarian cancer	0.00262	0.0363	CbGeAlD
Dexamethasone—CYP3A4—Paclitaxel—ovarian cancer	0.00241	0.00603	CbGbCtD
Dexamethasone—ABCB1—Doxorubicin—ovarian cancer	0.00217	0.00542	CbGbCtD
Dexamethasone—ANXA1—oviduct—ovarian cancer	0.00212	0.0295	CbGeAlD
Dexamethasone—CYP2D6—Doxorubicin—ovarian cancer	0.00204	0.00511	CbGbCtD
Dexamethasone—CYP3A4—Docetaxel—ovarian cancer	0.00174	0.00436	CbGbCtD
Dexamethasone—PTGS2—ovarian follicle—ovarian cancer	0.00145	0.0202	CbGeAlD
Dexamethasone—CYP3A4—Doxorubicin—ovarian cancer	0.0013	0.00325	CbGbCtD
Dexamethasone—PGR—oviduct—ovarian cancer	0.00128	0.0177	CbGeAlD
Dexamethasone—NR0B1—gonad—ovarian cancer	0.000814	0.0113	CbGeAlD
Dexamethasone—NR0B1—female reproductive system—ovarian cancer	0.000727	0.0101	CbGeAlD
Dexamethasone—CYP3A43—testis—ovarian cancer	0.000708	0.00982	CbGeAlD
Dexamethasone—PLA2G1B—epithelium—ovarian cancer	0.000697	0.00967	CbGeAlD
Dexamethasone—ANXA1—myometrium—ovarian cancer	0.00068	0.00942	CbGeAlD
Dexamethasone—NR0B1—female gonad—ovarian cancer	0.000662	0.00918	CbGeAlD
Dexamethasone—ANXA1—embryo—ovarian cancer	0.000654	0.00906	CbGeAlD
Dexamethasone—NR0B1—testis—ovarian cancer	0.000587	0.00814	CbGeAlD
Dexamethasone—CYP4A11—vagina—ovarian cancer	0.000566	0.00784	CbGeAlD
Dexamethasone—ANXA1—epithelium—ovarian cancer	0.000533	0.0074	CbGeAlD
Dexamethasone—ANXA1—uterine cervix—ovarian cancer	0.000529	0.00733	CbGeAlD
Dexamethasone—PLA2G1B—female reproductive system—ovarian cancer	0.000518	0.00718	CbGeAlD
Dexamethasone—ANXA1—decidua—ovarian cancer	0.000504	0.00699	CbGeAlD
Dexamethasone—ANXA1—endometrium—ovarian cancer	0.000478	0.00663	CbGeAlD
Dexamethasone—PLA2G1B—female gonad—ovarian cancer	0.000471	0.00654	CbGeAlD
Dexamethasone—ANXA1—gonad—ovarian cancer	0.000444	0.00615	CbGeAlD
Dexamethasone—ANXA1—uterus—ovarian cancer	0.000441	0.00611	CbGeAlD
Dexamethasone—NR3C2—myometrium—ovarian cancer	0.00044	0.0061	CbGeAlD
Dexamethasone—CYP11A1—decidua—ovarian cancer	0.00042	0.00583	CbGeAlD
Dexamethasone—PLA2G1B—testis—ovarian cancer	0.000418	0.0058	CbGeAlD
Dexamethasone—PGR—myometrium—ovarian cancer	0.000409	0.00567	CbGeAlD
Dexamethasone—CYP17A1—gonad—ovarian cancer	0.000398	0.00551	CbGeAlD
Dexamethasone—ANXA1—female reproductive system—ovarian cancer	0.000396	0.00549	CbGeAlD
Dexamethasone—ANXA1—bone marrow—ovarian cancer	0.000374	0.00519	CbGeAlD
Dexamethasone—CYP11A1—gonad—ovarian cancer	0.00037	0.00513	CbGeAlD
Dexamethasone—ANXA1—female gonad—ovarian cancer	0.000361	0.005	CbGeAlD
Dexamethasone—ANXA1—vagina—ovarian cancer	0.000358	0.00497	CbGeAlD
Dexamethasone—CYP17A1—female reproductive system—ovarian cancer	0.000355	0.00492	CbGeAlD
Dexamethasone—NR3C2—uterine cervix—ovarian cancer	0.000342	0.00475	CbGeAlD
Dexamethasone—CYP11A1—female reproductive system—ovarian cancer	0.00033	0.00458	CbGeAlD
Dexamethasone—ABCB11—testis—ovarian cancer	0.000325	0.00451	CbGeAlD
Dexamethasone—CYP17A1—female gonad—ovarian cancer	0.000323	0.00448	CbGeAlD
Dexamethasone—PGR—epithelium—ovarian cancer	0.000321	0.00445	CbGeAlD
Dexamethasone—ANXA1—testis—ovarian cancer	0.00032	0.00443	CbGeAlD
Dexamethasone—PGR—uterine cervix—ovarian cancer	0.000318	0.00441	CbGeAlD
Dexamethasone—NR3C2—endometrium—ovarian cancer	0.00031	0.0043	CbGeAlD
Dexamethasone—PGR—decidua—ovarian cancer	0.000303	0.00421	CbGeAlD
Dexamethasone—CYP11A1—female gonad—ovarian cancer	0.000301	0.00417	CbGeAlD
Dexamethasone—PGR—endometrium—ovarian cancer	0.000288	0.00399	CbGeAlD
Dexamethasone—CYP17A1—testis—ovarian cancer	0.000287	0.00397	CbGeAlD
Dexamethasone—NR3C2—uterus—ovarian cancer	0.000285	0.00396	CbGeAlD
Dexamethasone—CYP11A1—testis—ovarian cancer	0.000267	0.0037	CbGeAlD
Dexamethasone—PGR—uterus—ovarian cancer	0.000265	0.00368	CbGeAlD
Dexamethasone—CYP19A1—endometrium—ovarian cancer	0.000259	0.00359	CbGeAlD
Dexamethasone—NR3C2—female reproductive system—ovarian cancer	0.000257	0.00356	CbGeAlD
Dexamethasone—ABCG2—myometrium—ovarian cancer	0.000256	0.00355	CbGeAlD
Dexamethasone—CYP1B1—decidua—ovarian cancer	0.000255	0.00354	CbGeAlD
Dexamethasone—CYP2A6—vagina—ovarian cancer	0.000248	0.00343	CbGeAlD
Dexamethasone—CYP19A1—gonad—ovarian cancer	0.00024	0.00333	CbGeAlD
Dexamethasone—CYP19A1—uterus—ovarian cancer	0.000239	0.00331	CbGeAlD
Dexamethasone—PGR—female reproductive system—ovarian cancer	0.000239	0.00331	CbGeAlD
Dexamethasone—NR3C1—myometrium—ovarian cancer	0.000236	0.00327	CbGeAlD
Dexamethasone—Fluticasone Propionate—PGR—ovarian cancer	0.000235	0.226	CrCbGaD
Dexamethasone—NR3C2—female gonad—ovarian cancer	0.000233	0.00324	CbGeAlD
Dexamethasone—NR3C2—vagina—ovarian cancer	0.000232	0.00322	CbGeAlD
Dexamethasone—ANXA1—lymph node—ovarian cancer	0.000232	0.00321	CbGeAlD
Dexamethasone—NR3C1—embryo—ovarian cancer	0.000227	0.00315	CbGeAlD
Dexamethasone—CYP1B1—gonad—ovarian cancer	0.000225	0.00312	CbGeAlD
Dexamethasone—CYP1B1—uterus—ovarian cancer	0.000223	0.0031	CbGeAlD
Dexamethasone—PGR—female gonad—ovarian cancer	0.000217	0.00301	CbGeAlD
Dexamethasone—PGR—vagina—ovarian cancer	0.000216	0.00299	CbGeAlD
Dexamethasone—Betamethasone—PGR—ovarian cancer	0.000215	0.207	CrCbGaD
Dexamethasone—CYP19A1—female reproductive system—ovarian cancer	0.000215	0.00298	CbGeAlD
Dexamethasone—CYP17A1—lymph node—ovarian cancer	0.000208	0.00288	CbGeAlD
Dexamethasone—NR3C2—testis—ovarian cancer	0.000207	0.00287	CbGeAlD
Dexamethasone—ABCC2—female reproductive system—ovarian cancer	0.000205	0.00284	CbGeAlD
Dexamethasone—PTGS2—myometrium—ovarian cancer	0.000204	0.00283	CbGeAlD
Dexamethasone—CYP1B1—female reproductive system—ovarian cancer	0.000201	0.00278	CbGeAlD
Dexamethasone—ABCG2—uterine cervix—ovarian cancer	0.000199	0.00277	CbGeAlD
Dexamethasone—PTGS2—embryo—ovarian cancer	0.000196	0.00272	CbGeAlD
Dexamethasone—CYP19A1—female gonad—ovarian cancer	0.000195	0.00271	CbGeAlD
Dexamethasone—CYP11A1—lymph node—ovarian cancer	0.000193	0.00268	CbGeAlD
Dexamethasone—PGR—testis—ovarian cancer	0.000192	0.00267	CbGeAlD
Dexamethasone—CYP1A1—epithelium—ovarian cancer	0.000191	0.00265	CbGeAlD
Dexamethasone—ABCG2—decidua—ovarian cancer	0.00019	0.00263	CbGeAlD
Dexamethasone—CYP1A1—uterine cervix—ovarian cancer	0.000189	0.00263	CbGeAlD
Dexamethasone—CYP2C8—endometrium—ovarian cancer	0.000186	0.00257	CbGeAlD
Dexamethasone—NR3C1—epithelium—ovarian cancer	0.000185	0.00257	CbGeAlD
Dexamethasone—CYP3A5—uterine cervix—ovarian cancer	0.000185	0.00257	CbGeAlD
Dexamethasone—NR3C1—uterine cervix—ovarian cancer	0.000184	0.00255	CbGeAlD
Dexamethasone—CYP1B1—female gonad—ovarian cancer	0.000183	0.00253	CbGeAlD
Dexamethasone—ABCG2—endometrium—ovarian cancer	0.00018	0.0025	CbGeAlD
Dexamethasone—SLCO1A2—testis—ovarian cancer	0.000178	0.00246	CbGeAlD
Dexamethasone—NR3C1—decidua—ovarian cancer	0.000175	0.00243	CbGeAlD
Dexamethasone—Fluoxymesterone—ESR1—ovarian cancer	0.000174	0.168	CrCbGaD
Dexamethasone—CYP19A1—testis—ovarian cancer	0.000173	0.0024	CbGeAlD
Dexamethasone—ABCG2—uterus—ovarian cancer	0.000166	0.0023	CbGeAlD
Dexamethasone—NR3C1—endometrium—ovarian cancer	0.000166	0.0023	CbGeAlD
Dexamethasone—ABCC2—testis—ovarian cancer	0.000165	0.00229	CbGeAlD
Dexamethasone—CYP1B1—testis—ovarian cancer	0.000162	0.00225	CbGeAlD
Dexamethasone—PTGS2—epithelium—ovarian cancer	0.00016	0.00222	CbGeAlD
Dexamethasone—CYP2C19—vagina—ovarian cancer	0.000159	0.00221	CbGeAlD
Dexamethasone—PTGS2—uterine cervix—ovarian cancer	0.000159	0.0022	CbGeAlD
Dexamethasone—CYP1A1—uterus—ovarian cancer	0.000158	0.00219	CbGeAlD
Dexamethasone—CYP2B6—gonad—ovarian cancer	0.000154	0.00214	CbGeAlD
Dexamethasone—NR3C1—gonad—ovarian cancer	0.000154	0.00214	CbGeAlD
Dexamethasone—CYP2C8—female reproductive system—ovarian cancer	0.000154	0.00213	CbGeAlD
Dexamethasone—NR3C1—uterus—ovarian cancer	0.000153	0.00212	CbGeAlD
Dexamethasone—NR3C2—lymph node—ovarian cancer	0.00015	0.00208	CbGeAlD
Dexamethasone—PTGS2—endometrium—ovarian cancer	0.000144	0.00199	CbGeAlD
Dexamethasone—CYP1A1—female reproductive system—ovarian cancer	0.000142	0.00197	CbGeAlD
Dexamethasone—ABCG2—bone marrow—ovarian cancer	0.000141	0.00196	CbGeAlD
Dexamethasone—PGR—lymph node—ovarian cancer	0.00014	0.00193	CbGeAlD
Dexamethasone—CYP2C8—vagina—ovarian cancer	0.000139	0.00193	CbGeAlD
Dexamethasone—CYP2B6—female reproductive system—ovarian cancer	0.000138	0.00191	CbGeAlD
Dexamethasone—NR3C1—female reproductive system—ovarian cancer	0.000138	0.00191	CbGeAlD
Dexamethasone—CYP2C9—female reproductive system—ovarian cancer	0.000137	0.00189	CbGeAlD
Dexamethasone—ABCG2—female gonad—ovarian cancer	0.000136	0.00189	CbGeAlD
Dexamethasone—ABCG2—vagina—ovarian cancer	0.000135	0.00187	CbGeAlD
Dexamethasone—PTGS2—uterus—ovarian cancer	0.000133	0.00184	CbGeAlD
Dexamethasone—NR3C1—bone marrow—ovarian cancer	0.00013	0.0018	CbGeAlD
Dexamethasone—CYP2E1—female reproductive system—ovarian cancer	0.000129	0.00179	CbGeAlD
Dexamethasone—CYP1A1—female gonad—ovarian cancer	0.000129	0.00179	CbGeAlD
Dexamethasone—CYP1A1—vagina—ovarian cancer	0.000128	0.00178	CbGeAlD
Dexamethasone—ABCB1—myometrium—ovarian cancer	0.000126	0.00175	CbGeAlD
Dexamethasone—CYP3A5—female gonad—ovarian cancer	0.000126	0.00175	CbGeAlD
Dexamethasone—CYP19A1—lymph node—ovarian cancer	0.000126	0.00174	CbGeAlD
Dexamethasone—CYP3A5—vagina—ovarian cancer	0.000125	0.00174	CbGeAlD
Dexamethasone—NR3C1—female gonad—ovarian cancer	0.000125	0.00174	CbGeAlD
Dexamethasone—CYP2B6—vagina—ovarian cancer	0.000125	0.00173	CbGeAlD
Dexamethasone—NR3C1—vagina—ovarian cancer	0.000124	0.00173	CbGeAlD
Dexamethasone—CYP2C8—testis—ovarian cancer	0.000124	0.00172	CbGeAlD
Dexamethasone—ABCB1—embryo—ovarian cancer	0.000122	0.00169	CbGeAlD
Dexamethasone—ABCG2—testis—ovarian cancer	0.000121	0.00167	CbGeAlD
Dexamethasone—ABCC2—lymph node—ovarian cancer	0.00012	0.00166	CbGeAlD
Dexamethasone—PTGS2—female reproductive system—ovarian cancer	0.000119	0.00165	CbGeAlD
Dexamethasone—CYP1B1—lymph node—ovarian cancer	0.000117	0.00163	CbGeAlD
Dexamethasone—PTGS2—bone marrow—ovarian cancer	0.000112	0.00156	CbGeAlD
Dexamethasone—CYP2B6—testis—ovarian cancer	0.000111	0.00154	CbGeAlD
Dexamethasone—NR3C1—testis—ovarian cancer	0.000111	0.00154	CbGeAlD
Dexamethasone—PTGS2—female gonad—ovarian cancer	0.000108	0.0015	CbGeAlD
Dexamethasone—PTGS2—vagina—ovarian cancer	0.000108	0.00149	CbGeAlD
Dexamethasone—Fluticasone furoate—ABCB1—ovarian cancer	0.000105	0.101	CrCbGaD
Dexamethasone—CYP2E1—testis—ovarian cancer	0.000104	0.00145	CbGeAlD
Dexamethasone—CYP3A4—female reproductive system—ovarian cancer	0.000104	0.00144	CbGeAlD
Dexamethasone—CYP2D6—female reproductive system—ovarian cancer	0.000102	0.00142	CbGeAlD
Dexamethasone—ABCB1—epithelium—ovarian cancer	9.92e-05	0.00138	CbGeAlD
Dexamethasone—ABCB1—uterine cervix—ovarian cancer	9.83e-05	0.00136	CbGeAlD
Dexamethasone—ABCB1—decidua—ovarian cancer	9.37e-05	0.0013	CbGeAlD
Dexamethasone—CYP2D6—female gonad—ovarian cancer	9.32e-05	0.00129	CbGeAlD
Dexamethasone—Pruritus—Melphalan—ovarian cancer	9.05e-05	0.00111	CcSEcCtD
Dexamethasone—Anaphylactoid reaction—Epirubicin—ovarian cancer	9.03e-05	0.0011	CcSEcCtD
Dexamethasone—Haemoglobin—Docetaxel—ovarian cancer	9.01e-05	0.0011	CcSEcCtD
Dexamethasone—Haemorrhage—Docetaxel—ovarian cancer	8.97e-05	0.0011	CcSEcCtD
Dexamethasone—Eye pain—Doxorubicin—ovarian cancer	8.96e-05	0.0011	CcSEcCtD
Dexamethasone—Cardiac failure—Epirubicin—ovarian cancer	8.96e-05	0.0011	CcSEcCtD
Dexamethasone—Diarrhoea—Topotecan—ovarian cancer	8.94e-05	0.00109	CcSEcCtD
Dexamethasone—Lethargy—Epirubicin—ovarian cancer	8.92e-05	0.00109	CcSEcCtD
Dexamethasone—Cardiac failure congestive—Doxorubicin—ovarian cancer	8.92e-05	0.00109	CcSEcCtD
Dexamethasone—ABCB1—endometrium—ovarian cancer	8.89e-05	0.00123	CbGeAlD
Dexamethasone—Urticaria—Vinorelbine—ovarian cancer	8.88e-05	0.00109	CcSEcCtD
Dexamethasone—Body temperature increased—Vinorelbine—ovarian cancer	8.83e-05	0.00108	CcSEcCtD
Dexamethasone—Abdominal pain—Vinorelbine—ovarian cancer	8.83e-05	0.00108	CcSEcCtD
Dexamethasone—Diarrhoea—Melphalan—ovarian cancer	8.75e-05	0.00107	CcSEcCtD
Dexamethasone—Osteoarthritis—Epirubicin—ovarian cancer	8.74e-05	0.00107	CcSEcCtD
Dexamethasone—ABCG2—lymph node—ovarian cancer	8.74e-05	0.00121	CbGeAlD
Dexamethasone—Nausea—Chlorambucil—ovarian cancer	8.72e-05	0.00107	CcSEcCtD
Dexamethasone—Visual impairment—Docetaxel—ovarian cancer	8.64e-05	0.00106	CcSEcCtD
Dexamethasone—Dizziness—Topotecan—ovarian cancer	8.64e-05	0.00106	CcSEcCtD
Dexamethasone—Increased appetite—Doxorubicin—ovarian cancer	8.61e-05	0.00105	CcSEcCtD
Dexamethasone—Affect lability—Epirubicin—ovarian cancer	8.61e-05	0.00105	CcSEcCtD
Dexamethasone—Migraine—Epirubicin—ovarian cancer	8.61e-05	0.00105	CcSEcCtD
Dexamethasone—Ill-defined disorder—Paclitaxel—ovarian cancer	8.55e-05	0.00104	CcSEcCtD
Dexamethasone—Dermatitis bullous—Doxorubicin—ovarian cancer	8.46e-05	0.00103	CcSEcCtD
Dexamethasone—Angioedema—Paclitaxel—ovarian cancer	8.42e-05	0.00103	CcSEcCtD
Dexamethasone—Eye disorder—Docetaxel—ovarian cancer	8.38e-05	0.00102	CcSEcCtD
Dexamethasone—Anaphylactoid reaction—Doxorubicin—ovarian cancer	8.36e-05	0.00102	CcSEcCtD
Dexamethasone—Methylprednisolone—ABCB1—ovarian cancer	8.36e-05	0.0805	CrCbGaD
Dexamethasone—Cardiac arrest—Epirubicin—ovarian cancer	8.31e-05	0.00102	CcSEcCtD
Dexamethasone—Vomiting—Topotecan—ovarian cancer	8.31e-05	0.00102	CcSEcCtD
Dexamethasone—Malaise—Paclitaxel—ovarian cancer	8.31e-05	0.00102	CcSEcCtD
Dexamethasone—CYP1A1—lymph node—ovarian cancer	8.3e-05	0.00115	CbGeAlD
Dexamethasone—Cardiac failure—Doxorubicin—ovarian cancer	8.29e-05	0.00101	CcSEcCtD
Dexamethasone—Mood swings—Epirubicin—ovarian cancer	8.28e-05	0.00101	CcSEcCtD
Dexamethasone—Vertigo—Paclitaxel—ovarian cancer	8.27e-05	0.00101	CcSEcCtD
Dexamethasone—CYP2D6—testis—ovarian cancer	8.27e-05	0.00115	CbGeAlD
Dexamethasone—Syncope—Paclitaxel—ovarian cancer	8.26e-05	0.00101	CcSEcCtD
Dexamethasone—Lethargy—Doxorubicin—ovarian cancer	8.26e-05	0.00101	CcSEcCtD
Dexamethasone—ABCB1—gonad—ovarian cancer	8.25e-05	0.00114	CbGeAlD
Dexamethasone—Rash—Topotecan—ovarian cancer	8.24e-05	0.00101	CcSEcCtD
Dexamethasone—Dermatitis—Topotecan—ovarian cancer	8.23e-05	0.00101	CcSEcCtD
Dexamethasone—ABCB1—uterus—ovarian cancer	8.2e-05	0.00114	CbGeAlD
Dexamethasone—Headache—Topotecan—ovarian cancer	8.18e-05	0.001	CcSEcCtD
Dexamethasone—Angiopathy—Docetaxel—ovarian cancer	8.14e-05	0.000995	CcSEcCtD
Dexamethasone—Vomiting—Melphalan—ovarian cancer	8.13e-05	0.000994	CcSEcCtD
Dexamethasone—Loss of consciousness—Paclitaxel—ovarian cancer	8.09e-05	0.00099	CcSEcCtD
Dexamethasone—Osteoarthritis—Doxorubicin—ovarian cancer	8.09e-05	0.000989	CcSEcCtD
Dexamethasone—Rash—Melphalan—ovarian cancer	8.06e-05	0.000986	CcSEcCtD
Dexamethasone—Dermatitis—Melphalan—ovarian cancer	8.06e-05	0.000985	CcSEcCtD
Dexamethasone—NR3C1—lymph node—ovarian cancer	8.05e-05	0.00112	CbGeAlD
Dexamethasone—Asthenia—Vinorelbine—ovarian cancer	8.02e-05	0.00098	CcSEcCtD
Dexamethasone—Dry skin—Epirubicin—ovarian cancer	8.01e-05	0.00098	CcSEcCtD
Dexamethasone—Arrhythmia—Docetaxel—ovarian cancer	8.01e-05	0.000979	CcSEcCtD
Dexamethasone—Convulsion—Paclitaxel—ovarian cancer	7.98e-05	0.000976	CcSEcCtD
Dexamethasone—Migraine—Doxorubicin—ovarian cancer	7.96e-05	0.000973	CcSEcCtD
Dexamethasone—Affect lability—Doxorubicin—ovarian cancer	7.96e-05	0.000973	CcSEcCtD
Dexamethasone—Hypokalaemia—Epirubicin—ovarian cancer	7.96e-05	0.000973	CcSEcCtD
Dexamethasone—Hypertension—Paclitaxel—ovarian cancer	7.95e-05	0.000972	CcSEcCtD
Dexamethasone—Alopecia—Docetaxel—ovarian cancer	7.92e-05	0.000969	CcSEcCtD
Dexamethasone—Pruritus—Vinorelbine—ovarian cancer	7.91e-05	0.000967	CcSEcCtD
Dexamethasone—Myalgia—Paclitaxel—ovarian cancer	7.84e-05	0.000959	CcSEcCtD
Dexamethasone—Anxiety—Paclitaxel—ovarian cancer	7.81e-05	0.000955	CcSEcCtD
Dexamethasone—Erythema—Docetaxel—ovarian cancer	7.81e-05	0.000954	CcSEcCtD
Dexamethasone—Nausea—Topotecan—ovarian cancer	7.76e-05	0.000949	CcSEcCtD
Dexamethasone—Discomfort—Paclitaxel—ovarian cancer	7.75e-05	0.000947	CcSEcCtD
Dexamethasone—Muscular weakness—Epirubicin—ovarian cancer	7.71e-05	0.000943	CcSEcCtD
Dexamethasone—Cardiac arrest—Doxorubicin—ovarian cancer	7.69e-05	0.00094	CcSEcCtD
Dexamethasone—Mood swings—Doxorubicin—ovarian cancer	7.66e-05	0.000937	CcSEcCtD
Dexamethasone—Diarrhoea—Vinorelbine—ovarian cancer	7.65e-05	0.000935	CcSEcCtD
Dexamethasone—Nausea—Melphalan—ovarian cancer	7.6e-05	0.000929	CcSEcCtD
Dexamethasone—Oedema—Paclitaxel—ovarian cancer	7.52e-05	0.000919	CcSEcCtD
Dexamethasone—Anaphylactic shock—Paclitaxel—ovarian cancer	7.52e-05	0.000919	CcSEcCtD
Dexamethasone—Infection—Paclitaxel—ovarian cancer	7.47e-05	0.000913	CcSEcCtD
Dexamethasone—Dry skin—Doxorubicin—ovarian cancer	7.42e-05	0.000907	CcSEcCtD
Dexamethasone—Shock—Paclitaxel—ovarian cancer	7.39e-05	0.000904	CcSEcCtD
Dexamethasone—Dizziness—Vinorelbine—ovarian cancer	7.39e-05	0.000903	CcSEcCtD
Dexamethasone—Nervous system disorder—Paclitaxel—ovarian cancer	7.37e-05	0.000901	CcSEcCtD
Dexamethasone—ABCB1—female reproductive system—ovarian cancer	7.37e-05	0.00102	CbGeAlD
Dexamethasone—Hypokalaemia—Doxorubicin—ovarian cancer	7.36e-05	0.0009	CcSEcCtD
Dexamethasone—Thrombocytopenia—Paclitaxel—ovarian cancer	7.36e-05	0.0009	CcSEcCtD
Dexamethasone—Tachycardia—Paclitaxel—ovarian cancer	7.34e-05	0.000897	CcSEcCtD
Dexamethasone—Hyperhidrosis—Paclitaxel—ovarian cancer	7.27e-05	0.000888	CcSEcCtD
Dexamethasone—Anorexia—Paclitaxel—ovarian cancer	7.16e-05	0.000876	CcSEcCtD
Dexamethasone—Muscular weakness—Doxorubicin—ovarian cancer	7.13e-05	0.000872	CcSEcCtD
Dexamethasone—Vomiting—Vinorelbine—ovarian cancer	7.11e-05	0.000869	CcSEcCtD
Dexamethasone—Rash—Vinorelbine—ovarian cancer	7.05e-05	0.000861	CcSEcCtD
Dexamethasone—Dermatitis—Vinorelbine—ovarian cancer	7.04e-05	0.000861	CcSEcCtD
Dexamethasone—Hypotension—Paclitaxel—ovarian cancer	7.02e-05	0.000859	CcSEcCtD
Dexamethasone—Headache—Vinorelbine—ovarian cancer	7e-05	0.000856	CcSEcCtD
Dexamethasone—Syncope—Docetaxel—ovarian cancer	7e-05	0.000856	CcSEcCtD
Dexamethasone—PTGS2—lymph node—ovarian cancer	6.97e-05	0.000966	CbGeAlD
Dexamethasone—ABCB1—bone marrow—ovarian cancer	6.96e-05	0.000965	CbGeAlD
Dexamethasone—Weight increased—Epirubicin—ovarian cancer	6.88e-05	0.000841	CcSEcCtD
Dexamethasone—Loss of consciousness—Docetaxel—ovarian cancer	6.86e-05	0.000839	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	6.85e-05	0.000837	CcSEcCtD
Dexamethasone—Weight decreased—Epirubicin—ovarian cancer	6.84e-05	0.000836	CcSEcCtD
Dexamethasone—Hyperglycaemia—Epirubicin—ovarian cancer	6.82e-05	0.000833	CcSEcCtD
Dexamethasone—Insomnia—Paclitaxel—ovarian cancer	6.8e-05	0.000831	CcSEcCtD
Dexamethasone—Convulsion—Docetaxel—ovarian cancer	6.76e-05	0.000827	CcSEcCtD
Dexamethasone—Paraesthesia—Paclitaxel—ovarian cancer	6.75e-05	0.000825	CcSEcCtD
Dexamethasone—Hypertension—Docetaxel—ovarian cancer	6.74e-05	0.000824	CcSEcCtD
Dexamethasone—ABCB1—female gonad—ovarian cancer	6.7e-05	0.00093	CbGeAlD
Dexamethasone—ABCB1—vagina—ovarian cancer	6.66e-05	0.000924	CbGeAlD
Dexamethasone—Myalgia—Docetaxel—ovarian cancer	6.65e-05	0.000812	CcSEcCtD
Dexamethasone—Nausea—Vinorelbine—ovarian cancer	6.64e-05	0.000811	CcSEcCtD
Dexamethasone—Dyspepsia—Paclitaxel—ovarian cancer	6.62e-05	0.000809	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Epirubicin—ovarian cancer	6.6e-05	0.000807	CcSEcCtD
Dexamethasone—Conjunctivitis—Epirubicin—ovarian cancer	6.55e-05	0.000801	CcSEcCtD
Dexamethasone—Decreased appetite—Paclitaxel—ovarian cancer	6.53e-05	0.000799	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	6.49e-05	0.000793	CcSEcCtD
Dexamethasone—Fatigue—Paclitaxel—ovarian cancer	6.48e-05	0.000792	CcSEcCtD
Dexamethasone—Pain—Paclitaxel—ovarian cancer	6.43e-05	0.000786	CcSEcCtD
Dexamethasone—Prednisone—ABCB1—ovarian cancer	6.39e-05	0.0616	CrCbGaD
Dexamethasone—Anaphylactic shock—Docetaxel—ovarian cancer	6.37e-05	0.000779	CcSEcCtD
Dexamethasone—Oedema—Docetaxel—ovarian cancer	6.37e-05	0.000779	CcSEcCtD
Dexamethasone—Weight increased—Doxorubicin—ovarian cancer	6.36e-05	0.000778	CcSEcCtD
Dexamethasone—Infection—Docetaxel—ovarian cancer	6.33e-05	0.000774	CcSEcCtD
Dexamethasone—Weight decreased—Doxorubicin—ovarian cancer	6.33e-05	0.000773	CcSEcCtD
Dexamethasone—Hyperglycaemia—Doxorubicin—ovarian cancer	6.31e-05	0.000771	CcSEcCtD
Dexamethasone—Shock—Docetaxel—ovarian cancer	6.27e-05	0.000766	CcSEcCtD
Dexamethasone—Nervous system disorder—Docetaxel—ovarian cancer	6.25e-05	0.000764	CcSEcCtD
Dexamethasone—Thrombocytopenia—Docetaxel—ovarian cancer	6.24e-05	0.000763	CcSEcCtD
Dexamethasone—Tachycardia—Docetaxel—ovarian cancer	6.22e-05	0.00076	CcSEcCtD
Dexamethasone—Feeling abnormal—Paclitaxel—ovarian cancer	6.19e-05	0.000757	CcSEcCtD
Dexamethasone—Bradycardia—Epirubicin—ovarian cancer	6.16e-05	0.000753	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Paclitaxel—ovarian cancer	6.15e-05	0.000751	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Doxorubicin—ovarian cancer	6.11e-05	0.000747	CcSEcCtD
Dexamethasone—Haemoglobin—Epirubicin—ovarian cancer	6.08e-05	0.000743	CcSEcCtD
Dexamethasone—Anorexia—Docetaxel—ovarian cancer	6.07e-05	0.000742	CcSEcCtD
Dexamethasone—Conjunctivitis—Doxorubicin—ovarian cancer	6.06e-05	0.000741	CcSEcCtD
Dexamethasone—Haemorrhage—Epirubicin—ovarian cancer	6.05e-05	0.000739	CcSEcCtD
Dexamethasone—Urticaria—Paclitaxel—ovarian cancer	5.97e-05	0.00073	CcSEcCtD
Dexamethasone—Hypotension—Docetaxel—ovarian cancer	5.95e-05	0.000728	CcSEcCtD
Dexamethasone—ABCB1—testis—ovarian cancer	5.95e-05	0.000825	CbGeAlD
Dexamethasone—Abdominal pain—Paclitaxel—ovarian cancer	5.94e-05	0.000726	CcSEcCtD
Dexamethasone—Body temperature increased—Paclitaxel—ovarian cancer	5.94e-05	0.000726	CcSEcCtD
Dexamethasone—Prednisolone—ABCB1—ovarian cancer	5.89e-05	0.0567	CrCbGaD
Dexamethasone—Visual impairment—Epirubicin—ovarian cancer	5.83e-05	0.000713	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	5.8e-05	0.00071	CcSEcCtD
Dexamethasone—Betamethasone—ABCB1—ovarian cancer	5.77e-05	0.0556	CrCbGaD
Dexamethasone—Insomnia—Docetaxel—ovarian cancer	5.76e-05	0.000704	CcSEcCtD
Dexamethasone—Paraesthesia—Docetaxel—ovarian cancer	5.72e-05	0.000699	CcSEcCtD
Dexamethasone—Bradycardia—Doxorubicin—ovarian cancer	5.7e-05	0.000697	CcSEcCtD
Dexamethasone—Eye disorder—Epirubicin—ovarian cancer	5.65e-05	0.000691	CcSEcCtD
Dexamethasone—Haemoglobin—Doxorubicin—ovarian cancer	5.62e-05	0.000688	CcSEcCtD
Dexamethasone—Dyspepsia—Docetaxel—ovarian cancer	5.61e-05	0.000686	CcSEcCtD
Dexamethasone—Haemorrhage—Doxorubicin—ovarian cancer	5.6e-05	0.000684	CcSEcCtD
Dexamethasone—Decreased appetite—Docetaxel—ovarian cancer	5.54e-05	0.000677	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Docetaxel—ovarian cancer	5.5e-05	0.000672	CcSEcCtD
Dexamethasone—Fatigue—Docetaxel—ovarian cancer	5.49e-05	0.000672	CcSEcCtD
Dexamethasone—Angiopathy—Epirubicin—ovarian cancer	5.49e-05	0.000671	CcSEcCtD
Dexamethasone—Pain—Docetaxel—ovarian cancer	5.45e-05	0.000666	CcSEcCtD
Dexamethasone—Arrhythmia—Epirubicin—ovarian cancer	5.4e-05	0.000661	CcSEcCtD
Dexamethasone—Visual impairment—Doxorubicin—ovarian cancer	5.39e-05	0.000659	CcSEcCtD
Dexamethasone—Asthenia—Paclitaxel—ovarian cancer	5.39e-05	0.000659	CcSEcCtD
Dexamethasone—Alopecia—Epirubicin—ovarian cancer	5.34e-05	0.000653	CcSEcCtD
Dexamethasone—Pruritus—Paclitaxel—ovarian cancer	5.32e-05	0.00065	CcSEcCtD
Dexamethasone—Erythema—Epirubicin—ovarian cancer	5.27e-05	0.000644	CcSEcCtD
Dexamethasone—Feeling abnormal—Docetaxel—ovarian cancer	5.25e-05	0.000642	CcSEcCtD
Dexamethasone—Eye disorder—Doxorubicin—ovarian cancer	5.23e-05	0.000639	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Docetaxel—ovarian cancer	5.21e-05	0.000637	CcSEcCtD
Dexamethasone—Diarrhoea—Paclitaxel—ovarian cancer	5.14e-05	0.000629	CcSEcCtD
Dexamethasone—Angiopathy—Doxorubicin—ovarian cancer	5.08e-05	0.000621	CcSEcCtD
Dexamethasone—Body temperature increased—Docetaxel—ovarian cancer	5.04e-05	0.000616	CcSEcCtD
Dexamethasone—Abdominal pain—Docetaxel—ovarian cancer	5.04e-05	0.000616	CcSEcCtD
Dexamethasone—Arrhythmia—Doxorubicin—ovarian cancer	5e-05	0.000611	CcSEcCtD
Dexamethasone—Dizziness—Paclitaxel—ovarian cancer	4.97e-05	0.000608	CcSEcCtD
Dexamethasone—Alopecia—Doxorubicin—ovarian cancer	4.95e-05	0.000605	CcSEcCtD
Dexamethasone—Ill-defined disorder—Epirubicin—ovarian cancer	4.89e-05	0.000597	CcSEcCtD
Dexamethasone—Erythema—Doxorubicin—ovarian cancer	4.87e-05	0.000596	CcSEcCtD
Dexamethasone—Vomiting—Paclitaxel—ovarian cancer	4.78e-05	0.000584	CcSEcCtD
Dexamethasone—Malaise—Epirubicin—ovarian cancer	4.75e-05	0.00058	CcSEcCtD
Dexamethasone—Rash—Paclitaxel—ovarian cancer	4.74e-05	0.000579	CcSEcCtD
Dexamethasone—Dermatitis—Paclitaxel—ovarian cancer	4.73e-05	0.000579	CcSEcCtD
Dexamethasone—Vertigo—Epirubicin—ovarian cancer	4.73e-05	0.000578	CcSEcCtD
Dexamethasone—Syncope—Epirubicin—ovarian cancer	4.72e-05	0.000577	CcSEcCtD
Dexamethasone—Headache—Paclitaxel—ovarian cancer	4.71e-05	0.000576	CcSEcCtD
Dexamethasone—Loss of consciousness—Epirubicin—ovarian cancer	4.63e-05	0.000566	CcSEcCtD
Dexamethasone—Asthenia—Docetaxel—ovarian cancer	4.57e-05	0.000559	CcSEcCtD
Dexamethasone—Convulsion—Epirubicin—ovarian cancer	4.56e-05	0.000558	CcSEcCtD
Dexamethasone—Hypertension—Epirubicin—ovarian cancer	4.55e-05	0.000556	CcSEcCtD
Dexamethasone—Ill-defined disorder—Doxorubicin—ovarian cancer	4.52e-05	0.000553	CcSEcCtD
Dexamethasone—Pruritus—Docetaxel—ovarian cancer	4.51e-05	0.000551	CcSEcCtD
Dexamethasone—Hydrocortisone—ABCB1—ovarian cancer	4.51e-05	0.0434	CrCbGaD
Dexamethasone—Myalgia—Epirubicin—ovarian cancer	4.48e-05	0.000548	CcSEcCtD
Dexamethasone—Anxiety—Epirubicin—ovarian cancer	4.47e-05	0.000546	CcSEcCtD
Dexamethasone—Nausea—Paclitaxel—ovarian cancer	4.46e-05	0.000546	CcSEcCtD
Dexamethasone—Discomfort—Epirubicin—ovarian cancer	4.43e-05	0.000541	CcSEcCtD
Dexamethasone—Malaise—Doxorubicin—ovarian cancer	4.39e-05	0.000537	CcSEcCtD
Dexamethasone—Vertigo—Doxorubicin—ovarian cancer	4.38e-05	0.000535	CcSEcCtD
Dexamethasone—Syncope—Doxorubicin—ovarian cancer	4.37e-05	0.000534	CcSEcCtD
Dexamethasone—Diarrhoea—Docetaxel—ovarian cancer	4.36e-05	0.000533	CcSEcCtD
Dexamethasone—ABCB1—lymph node—ovarian cancer	4.31e-05	0.000598	CbGeAlD
Dexamethasone—Anaphylactic shock—Epirubicin—ovarian cancer	4.3e-05	0.000525	CcSEcCtD
Dexamethasone—Oedema—Epirubicin—ovarian cancer	4.3e-05	0.000525	CcSEcCtD
Dexamethasone—Loss of consciousness—Doxorubicin—ovarian cancer	4.28e-05	0.000523	CcSEcCtD
Dexamethasone—Infection—Epirubicin—ovarian cancer	4.27e-05	0.000522	CcSEcCtD
Dexamethasone—Shock—Epirubicin—ovarian cancer	4.23e-05	0.000517	CcSEcCtD
Dexamethasone—Convulsion—Doxorubicin—ovarian cancer	4.22e-05	0.000516	CcSEcCtD
Dexamethasone—Nervous system disorder—Epirubicin—ovarian cancer	4.21e-05	0.000515	CcSEcCtD
Dexamethasone—Dizziness—Docetaxel—ovarian cancer	4.21e-05	0.000515	CcSEcCtD
Dexamethasone—Thrombocytopenia—Epirubicin—ovarian cancer	4.21e-05	0.000514	CcSEcCtD
Dexamethasone—Hypertension—Doxorubicin—ovarian cancer	4.21e-05	0.000514	CcSEcCtD
Dexamethasone—Tachycardia—Epirubicin—ovarian cancer	4.19e-05	0.000513	CcSEcCtD
Dexamethasone—Hyperhidrosis—Epirubicin—ovarian cancer	4.15e-05	0.000508	CcSEcCtD
Dexamethasone—Myalgia—Doxorubicin—ovarian cancer	4.15e-05	0.000507	CcSEcCtD
Dexamethasone—Anxiety—Doxorubicin—ovarian cancer	4.13e-05	0.000505	CcSEcCtD
Dexamethasone—Discomfort—Doxorubicin—ovarian cancer	4.1e-05	0.000501	CcSEcCtD
Dexamethasone—Anorexia—Epirubicin—ovarian cancer	4.1e-05	0.000501	CcSEcCtD
Dexamethasone—Vomiting—Docetaxel—ovarian cancer	4.05e-05	0.000495	CcSEcCtD
Dexamethasone—Rash—Docetaxel—ovarian cancer	4.02e-05	0.000491	CcSEcCtD
Dexamethasone—Hypotension—Epirubicin—ovarian cancer	4.02e-05	0.000491	CcSEcCtD
Dexamethasone—Dermatitis—Docetaxel—ovarian cancer	4.01e-05	0.000491	CcSEcCtD
Dexamethasone—Headache—Docetaxel—ovarian cancer	3.99e-05	0.000488	CcSEcCtD
Dexamethasone—Anaphylactic shock—Doxorubicin—ovarian cancer	3.98e-05	0.000486	CcSEcCtD
Dexamethasone—Oedema—Doxorubicin—ovarian cancer	3.98e-05	0.000486	CcSEcCtD
Dexamethasone—Infection—Doxorubicin—ovarian cancer	3.95e-05	0.000483	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	3.92e-05	0.000479	CcSEcCtD
Dexamethasone—Shock—Doxorubicin—ovarian cancer	3.91e-05	0.000478	CcSEcCtD
Dexamethasone—Nervous system disorder—Doxorubicin—ovarian cancer	3.9e-05	0.000477	CcSEcCtD
Dexamethasone—Thrombocytopenia—Doxorubicin—ovarian cancer	3.89e-05	0.000476	CcSEcCtD
Dexamethasone—Insomnia—Epirubicin—ovarian cancer	3.89e-05	0.000475	CcSEcCtD
Dexamethasone—Tachycardia—Doxorubicin—ovarian cancer	3.88e-05	0.000474	CcSEcCtD
Dexamethasone—Paraesthesia—Epirubicin—ovarian cancer	3.86e-05	0.000472	CcSEcCtD
Dexamethasone—Hyperhidrosis—Doxorubicin—ovarian cancer	3.84e-05	0.00047	CcSEcCtD
Dexamethasone—Anorexia—Doxorubicin—ovarian cancer	3.79e-05	0.000463	CcSEcCtD
Dexamethasone—Nausea—Docetaxel—ovarian cancer	3.78e-05	0.000463	CcSEcCtD
Dexamethasone—Dyspepsia—Epirubicin—ovarian cancer	3.78e-05	0.000462	CcSEcCtD
Dexamethasone—Decreased appetite—Epirubicin—ovarian cancer	3.74e-05	0.000457	CcSEcCtD
Dexamethasone—Hypotension—Doxorubicin—ovarian cancer	3.72e-05	0.000454	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Epirubicin—ovarian cancer	3.71e-05	0.000454	CcSEcCtD
Dexamethasone—Fatigue—Epirubicin—ovarian cancer	3.7e-05	0.000453	CcSEcCtD
Dexamethasone—Pain—Epirubicin—ovarian cancer	3.67e-05	0.000449	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.62e-05	0.000443	CcSEcCtD
Dexamethasone—Insomnia—Doxorubicin—ovarian cancer	3.6e-05	0.00044	CcSEcCtD
Dexamethasone—Paraesthesia—Doxorubicin—ovarian cancer	3.57e-05	0.000436	CcSEcCtD
Dexamethasone—Feeling abnormal—Epirubicin—ovarian cancer	3.54e-05	0.000433	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Epirubicin—ovarian cancer	3.51e-05	0.00043	CcSEcCtD
Dexamethasone—Dyspepsia—Doxorubicin—ovarian cancer	3.5e-05	0.000428	CcSEcCtD
Dexamethasone—Decreased appetite—Doxorubicin—ovarian cancer	3.46e-05	0.000423	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.43e-05	0.00042	CcSEcCtD
Dexamethasone—Fatigue—Doxorubicin—ovarian cancer	3.43e-05	0.000419	CcSEcCtD
Dexamethasone—Urticaria—Epirubicin—ovarian cancer	3.41e-05	0.000417	CcSEcCtD
Dexamethasone—Pain—Doxorubicin—ovarian cancer	3.4e-05	0.000416	CcSEcCtD
Dexamethasone—Body temperature increased—Epirubicin—ovarian cancer	3.4e-05	0.000415	CcSEcCtD
Dexamethasone—Abdominal pain—Epirubicin—ovarian cancer	3.4e-05	0.000415	CcSEcCtD
Dexamethasone—Feeling abnormal—Doxorubicin—ovarian cancer	3.28e-05	0.000401	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.25e-05	0.000397	CcSEcCtD
Dexamethasone—Urticaria—Doxorubicin—ovarian cancer	3.16e-05	0.000386	CcSEcCtD
Dexamethasone—Abdominal pain—Doxorubicin—ovarian cancer	3.14e-05	0.000384	CcSEcCtD
Dexamethasone—Body temperature increased—Doxorubicin—ovarian cancer	3.14e-05	0.000384	CcSEcCtD
Dexamethasone—Asthenia—Epirubicin—ovarian cancer	3.08e-05	0.000377	CcSEcCtD
Dexamethasone—Pruritus—Epirubicin—ovarian cancer	3.04e-05	0.000372	CcSEcCtD
Dexamethasone—Diarrhoea—Epirubicin—ovarian cancer	2.94e-05	0.000359	CcSEcCtD
Dexamethasone—Asthenia—Doxorubicin—ovarian cancer	2.85e-05	0.000349	CcSEcCtD
Dexamethasone—Dizziness—Epirubicin—ovarian cancer	2.84e-05	0.000347	CcSEcCtD
Dexamethasone—Pruritus—Doxorubicin—ovarian cancer	2.81e-05	0.000344	CcSEcCtD
Dexamethasone—Vomiting—Epirubicin—ovarian cancer	2.73e-05	0.000334	CcSEcCtD
Dexamethasone—Diarrhoea—Doxorubicin—ovarian cancer	2.72e-05	0.000333	CcSEcCtD
Dexamethasone—Rash—Epirubicin—ovarian cancer	2.71e-05	0.000331	CcSEcCtD
Dexamethasone—Dermatitis—Epirubicin—ovarian cancer	2.71e-05	0.000331	CcSEcCtD
Dexamethasone—Headache—Epirubicin—ovarian cancer	2.69e-05	0.000329	CcSEcCtD
Dexamethasone—Dizziness—Doxorubicin—ovarian cancer	2.63e-05	0.000321	CcSEcCtD
Dexamethasone—Nausea—Epirubicin—ovarian cancer	2.55e-05	0.000312	CcSEcCtD
Dexamethasone—Vomiting—Doxorubicin—ovarian cancer	2.53e-05	0.000309	CcSEcCtD
Dexamethasone—Rash—Doxorubicin—ovarian cancer	2.51e-05	0.000306	CcSEcCtD
Dexamethasone—Dermatitis—Doxorubicin—ovarian cancer	2.5e-05	0.000306	CcSEcCtD
Dexamethasone—Headache—Doxorubicin—ovarian cancer	2.49e-05	0.000305	CcSEcCtD
Dexamethasone—Nausea—Doxorubicin—ovarian cancer	2.36e-05	0.000289	CcSEcCtD
Dexamethasone—PGR—Signaling Pathways—ERBB2—ovarian cancer	3.93e-06	5.85e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—PTEN—ovarian cancer	3.92e-06	5.84e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—SLC5A5—ovarian cancer	3.92e-06	5.84e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—BRIP1—ovarian cancer	3.92e-06	5.83e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PPP1CC—ovarian cancer	3.92e-06	5.83e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—PIK3CB—ovarian cancer	3.88e-06	5.77e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MTOR—ovarian cancer	3.88e-06	5.77e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PIK3CD—ovarian cancer	3.86e-06	5.74e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	3.85e-06	5.74e-05	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—IL6—ovarian cancer	3.83e-06	5.7e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PIK3CG—ovarian cancer	3.82e-06	5.69e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—CAV1—ovarian cancer	3.81e-06	5.68e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	3.81e-06	5.66e-05	CbGpPWpGaD
Dexamethasone—NOS2—Disease—AKT1—ovarian cancer	3.8e-06	5.66e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.8e-06	5.66e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—SLC2A1—ovarian cancer	3.79e-06	5.64e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—CAV1—ovarian cancer	3.78e-06	5.63e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—TERT—ovarian cancer	3.76e-06	5.59e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PPP2R1A—ovarian cancer	3.73e-06	5.55e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CXCL8—ovarian cancer	3.72e-06	5.54e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	3.72e-06	5.54e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.71e-06	5.52e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—ABCB1—ovarian cancer	3.68e-06	5.47e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CDKN1B—ovarian cancer	3.64e-06	5.41e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CYP1B1—ovarian cancer	3.63e-06	5.41e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—TYMS—ovarian cancer	3.61e-06	5.37e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CASP3—ovarian cancer	3.57e-06	5.31e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—FASN—ovarian cancer	3.56e-06	5.3e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—IL2—ovarian cancer	3.56e-06	5.3e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—ABCB1—ovarian cancer	3.53e-06	5.26e-05	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—AKT1—ovarian cancer	3.53e-06	5.26e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	3.51e-06	5.23e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—SLC5A5—ovarian cancer	3.5e-06	5.21e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.5e-06	5.21e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PIK3CD—ovarian cancer	3.49e-06	5.19e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—PTEN—ovarian cancer	3.48e-06	5.18e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PIK3CG—ovarian cancer	3.47e-06	5.17e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—FASN—ovarian cancer	3.47e-06	5.17e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CAV1—ovarian cancer	3.47e-06	5.17e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CCND1—ovarian cancer	3.47e-06	5.17e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—TYMS—ovarian cancer	3.47e-06	5.17e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—CAV1—ovarian cancer	3.47e-06	5.16e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.46e-06	5.16e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—ABCB1—ovarian cancer	3.46e-06	5.15e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—ABCB1—ovarian cancer	3.45e-06	5.14e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PIK3CG—ovarian cancer	3.44e-06	5.13e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CTNNB1—ovarian cancer	3.44e-06	5.12e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—SLC5A5—ovarian cancer	3.42e-06	5.09e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—TYMS—ovarian cancer	3.4e-06	5.06e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—TYMS—ovarian cancer	3.39e-06	5.05e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—SLC2A1—ovarian cancer	3.38e-06	5.03e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MMP9—ovarian cancer	3.37e-06	5.02e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PIK3CB—ovarian cancer	3.36e-06	5.01e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PIK3CD—ovarian cancer	3.36e-06	5e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—PTEN—ovarian cancer	3.35e-06	4.99e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.31e-06	4.93e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—SLC2A1—ovarian cancer	3.3e-06	4.91e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—IL6ST—ovarian cancer	3.29e-06	4.9e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—FASN—ovarian cancer	3.27e-06	4.87e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—ABCB1—ovarian cancer	3.26e-06	4.86e-05	CbGpPWpGaD
Dexamethasone—CYP3A43—Metabolism—AKT1—ovarian cancer	3.26e-06	4.86e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—FASN—ovarian cancer	3.25e-06	4.83e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CYP1B1—ovarian cancer	3.24e-06	4.83e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	3.22e-06	4.8e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—SLC5A5—ovarian cancer	3.22e-06	4.79e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.21e-06	4.77e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—TYMS—ovarian cancer	3.2e-06	4.77e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—SLC5A5—ovarian cancer	3.19e-06	4.75e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CYP1B1—ovarian cancer	3.16e-06	4.71e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—APC—ovarian cancer	3.16e-06	4.71e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PIK3CG—ovarian cancer	3.16e-06	4.7e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—SLC2A1—ovarian cancer	3.11e-06	4.63e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—SLC2A1—ovarian cancer	3.08e-06	4.59e-05	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—PIK3CA—ovarian cancer	3.06e-06	4.55e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PIK3CD—ovarian cancer	3.05e-06	4.55e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PIK3CB—ovarian cancer	3.04e-06	4.52e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PIK3CD—ovarian cancer	3.03e-06	4.51e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—VEGFA—ovarian cancer	3.03e-06	4.5e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.02e-06	4.49e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—STAT3—ovarian cancer	3e-06	4.46e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—ABCB1—ovarian cancer	2.99e-06	4.45e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—NRAS—ovarian cancer	2.99e-06	4.45e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CYP1B1—ovarian cancer	2.98e-06	4.44e-05	CbGpPWpGaD
Dexamethasone—PGR—Gene Expression—AKT1—ovarian cancer	2.97e-06	4.42e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CYP1B1—ovarian cancer	2.96e-06	4.4e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—TYMS—ovarian cancer	2.94e-06	4.37e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PIK3CB—ovarian cancer	2.93e-06	4.36e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—CAV1—ovarian cancer	2.91e-06	4.33e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PTEN—ovarian cancer	2.91e-06	4.33e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	2.88e-06	4.28e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MAPK3—ovarian cancer	2.86e-06	4.26e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.86e-06	4.26e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PPP2R1A—ovarian cancer	2.81e-06	4.18e-05	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—PIK3CA—ovarian cancer	2.8e-06	4.16e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—CAV1—ovarian cancer	2.8e-06	4.16e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MYC—ovarian cancer	2.78e-06	4.14e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—PIK3CD—ovarian cancer	2.78e-06	4.14e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.78e-06	4.14e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PIK3CD—ovarian cancer	2.78e-06	4.13e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—PIK3CA—ovarian cancer	2.77e-06	4.12e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—CAV1—ovarian cancer	2.74e-06	4.08e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—CAV1—ovarian cancer	2.73e-06	4.07e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MAPK1—ovarian cancer	2.72e-06	4.05e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—EGFR—ovarian cancer	2.72e-06	4.05e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—ABCB1—ovarian cancer	2.67e-06	3.97e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PIK3CB—ovarian cancer	2.66e-06	3.96e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PIK3CG—ovarian cancer	2.65e-06	3.94e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.64e-06	3.94e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PIK3CB—ovarian cancer	2.64e-06	3.93e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—YAP1—ovarian cancer	2.63e-06	3.91e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PTEN—ovarian cancer	2.63e-06	3.91e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—TYMS—ovarian cancer	2.62e-06	3.9e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.62e-06	3.9e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.61e-06	3.88e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—CAV1—ovarian cancer	2.58e-06	3.84e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—KRAS—ovarian cancer	2.57e-06	3.83e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—TYMS—ovarian cancer	2.56e-06	3.81e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PIK3CG—ovarian cancer	2.55e-06	3.79e-05	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—MAPK3—ovarian cancer	2.54e-06	3.79e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PTEN—ovarian cancer	2.53e-06	3.76e-05	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—AKT1—ovarian cancer	2.5e-06	3.72e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PIK3CG—ovarian cancer	2.49e-06	3.71e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PIK3CG—ovarian cancer	2.49e-06	3.71e-05	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—MYC—ovarian cancer	2.47e-06	3.68e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.47e-06	3.67e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—ERBB2—ovarian cancer	2.46e-06	3.66e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—ABCB1—ovarian cancer	2.46e-06	3.66e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—PIK3CA—ovarian cancer	2.46e-06	3.65e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.43e-06	3.62e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—PIK3CB—ovarian cancer	2.42e-06	3.61e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—MTOR—ovarian cancer	2.42e-06	3.61e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PIK3CB—ovarian cancer	2.42e-06	3.6e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—TYMS—ovarian cancer	2.41e-06	3.59e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—TYMS—ovarian cancer	2.39e-06	3.56e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CAV1—ovarian cancer	2.37e-06	3.52e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—PIK3CA—ovarian cancer	2.36e-06	3.52e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PIK3CG—ovarian cancer	2.35e-06	3.5e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PIK3CD—ovarian cancer	2.33e-06	3.47e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PTEN—ovarian cancer	2.3e-06	3.42e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—TP53—ovarian cancer	2.29e-06	3.4e-05	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—AKT1—ovarian cancer	2.28e-06	3.4e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PTEN—ovarian cancer	2.28e-06	3.39e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CDKN1B—ovarian cancer	2.28e-06	3.39e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.26e-06	3.37e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—AKT1—ovarian cancer	2.26e-06	3.37e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PIK3CD—ovarian cancer	2.24e-06	3.33e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PIK3CD—ovarian cancer	2.19e-06	3.26e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PIK3CD—ovarian cancer	2.19e-06	3.26e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—HRAS—ovarian cancer	2.19e-06	3.25e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PIK3CG—ovarian cancer	2.16e-06	3.21e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CTNNB1—ovarian cancer	2.15e-06	3.2e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—FASN—ovarian cancer	2.14e-06	3.19e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CAV1—ovarian cancer	2.11e-06	3.15e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.11e-06	3.13e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—PTEN—ovarian cancer	2.1e-06	3.12e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—IL6—ovarian cancer	2.09e-06	3.11e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PTEN—ovarian cancer	2.09e-06	3.11e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PIK3CD—ovarian cancer	2.07e-06	3.08e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CAV1—ovarian cancer	2.06e-06	3.07e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PIK3CA—ovarian cancer	2.05e-06	3.05e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.03e-06	3.03e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PIK3CB—ovarian cancer	2.03e-06	3.02e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.02e-06	3.01e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—AKT1—ovarian cancer	2.01e-06	2.99e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PIK3CB—ovarian cancer	1.95e-06	2.91e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.95e-06	2.9e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CAV1—ovarian cancer	1.94e-06	2.89e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—AKT1—ovarian cancer	1.93e-06	2.87e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CAV1—ovarian cancer	1.93e-06	2.87e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.92e-06	2.87e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PIK3CB—ovarian cancer	1.91e-06	2.85e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PIK3CB—ovarian cancer	1.91e-06	2.84e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.9e-06	2.82e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.88e-06	2.8e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—STAT3—ovarian cancer	1.87e-06	2.79e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—NRAS—ovarian cancer	1.87e-06	2.78e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PIK3CA—ovarian cancer	1.85e-06	2.76e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.84e-06	2.74e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PIK3CB—ovarian cancer	1.8e-06	2.68e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—MAPK3—ovarian cancer	1.79e-06	2.66e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PIK3CA—ovarian cancer	1.78e-06	2.66e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.77e-06	2.64e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.76e-06	2.61e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PTEN—ovarian cancer	1.75e-06	2.61e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—MYC—ovarian cancer	1.74e-06	2.59e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.73e-06	2.57e-05	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—AKT1—ovarian cancer	1.72e-06	2.55e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—MAPK1—ovarian cancer	1.7e-06	2.54e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—EGFR—ovarian cancer	1.7e-06	2.54e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.69e-06	2.52e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PTEN—ovarian cancer	1.69e-06	2.51e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—AKT1—ovarian cancer	1.67e-06	2.49e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.65e-06	2.46e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PTEN—ovarian cancer	1.65e-06	2.46e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.65e-06	2.46e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PTEN—ovarian cancer	1.65e-06	2.45e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.62e-06	2.42e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—KRAS—ovarian cancer	1.61e-06	2.39e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PIK3CA—ovarian cancer	1.61e-06	2.39e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.61e-06	2.39e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—TYMS—ovarian cancer	1.58e-06	2.35e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PTEN—ovarian cancer	1.56e-06	2.32e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.56e-06	2.32e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.54e-06	2.3e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—AKT1—ovarian cancer	1.51e-06	2.25e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—PIK3CA—ovarian cancer	1.48e-06	2.2e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.47e-06	2.2e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PIK3CA—ovarian cancer	1.47e-06	2.2e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—AKT1—ovarian cancer	1.46e-06	2.17e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.44e-06	2.14e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PTEN—ovarian cancer	1.43e-06	2.13e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—HRAS—ovarian cancer	1.37e-06	2.04e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.36e-06	2.02e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.34e-06	2e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—AKT1—ovarian cancer	1.33e-06	1.97e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—AKT1—ovarian cancer	1.31e-06	1.96e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—IL6—ovarian cancer	1.31e-06	1.95e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PTEN—ovarian cancer	1.27e-06	1.9e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CAV1—ovarian cancer	1.27e-06	1.89e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PTEN—ovarian cancer	1.24e-06	1.85e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PIK3CA—ovarian cancer	1.24e-06	1.84e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—AKT1—ovarian cancer	1.21e-06	1.8e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—AKT1—ovarian cancer	1.2e-06	1.79e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PIK3CA—ovarian cancer	1.19e-06	1.77e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PTEN—ovarian cancer	1.17e-06	1.74e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PIK3CA—ovarian cancer	1.17e-06	1.73e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.16e-06	1.73e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PTEN—ovarian cancer	1.16e-06	1.73e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.16e-06	1.72e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PIK3CA—ovarian cancer	1.1e-06	1.64e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.02e-06	1.51e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—AKT1—ovarian cancer	1.01e-06	1.51e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PIK3CA—ovarian cancer	1.01e-06	1.5e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—AKT1—ovarian cancer	9.72e-07	1.45e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—AKT1—ovarian cancer	9.52e-07	1.42e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—AKT1—ovarian cancer	9.5e-07	1.41e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PIK3CA—ovarian cancer	8.99e-07	1.34e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—AKT1—ovarian cancer	8.98e-07	1.34e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	8.87e-07	1.32e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PIK3CA—ovarian cancer	8.78e-07	1.31e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PIK3CA—ovarian cancer	8.27e-07	1.23e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—AKT1—ovarian cancer	8.23e-07	1.22e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PIK3CA—ovarian cancer	8.2e-07	1.22e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PTEN—ovarian cancer	7.66e-07	1.14e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—AKT1—ovarian cancer	7.34e-07	1.09e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—AKT1—ovarian cancer	7.17e-07	1.07e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—AKT1—ovarian cancer	6.76e-07	1.01e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—AKT1—ovarian cancer	6.7e-07	9.97e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	5.41e-07	8.05e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—AKT1—ovarian cancer	4.42e-07	6.57e-06	CbGpPWpGaD
